Rhabdoid tumors are aggressive tumors that may arise in the kidney, soft tissue, central nervous system, or other organs. They are defined by SMARCB1 (INI1) or SMARCA4 alterations. Often, very young children are affected, and the prognosis is dismal. Four patients with primary atypical teratoid rhabdoid tumor (AT/RT, a rhabdoid tumor in the central nervous system) were treated by resection and high dose chemotherapy. Tazemetostat was introduced after completion of chemotherapy. Three patients have achieved an event free survival of 32, 34, and 30 months respectively. One progressed and died. His overall survival was 20 months. One patient was treated for a relapsed atypical teratoid rhabdoid tumor. The treatment combined metronomic therapy, radiotherapy, tazemetostat and immunotherapy. This patient died of disease progression, with an overall survival of 37 months. One patient was treated for a rhabdoid tumor of the ovary. Tazemetostat was given as maintenance after resection, chemotherapy, and radiotherapy, concomitantly with immunotherapy. Her event free survival is 44 months. Only approximately 40% of patients with rhabdoid tumors achieve long-term survival. Nearly all relapses occur within two years from diagnosis. The event free survival of four of the six patients in our cohort has exceeded this timepoint. Tazemetostat has been mostly tested as a single agent in the relapsed setting. We present promising results when applied as maintenance or add on in the first line treatment.

Department of Biology Faculty of Medicine and Central European Institute of Technology Masaryk University 62500 Brno Czechia

Department of Hospital Pharmacy University Hospital Brno and Faculty of Medicine Masaryk University 62500 Brno Czechia

Department of Laboratory Medicine University Hospital Brno and Department of Laboratory Methods Faculty of Medicine Masaryk University 62500 Brno Czechia

Department of Pathology University Hospital Brno and Faculty of Medicine Masaryk University Brno 62500 Czechia

Department of Pediatric Oncology University Hospital Brno and Faculty of Medicine Masaryk University 62500 Brno Czechia

Department of Pharmacology and Toxicology Faculty of Pharmacy Masaryk University 62500 Brno Czechia

Department of Pharmacology Faculty of Medicine Masaryk University 62500 Brno Czechia

Zobrazit více v PubMed

Geller JI, Roth JJ, Biegel JA. Biology and treatment of rhabdoid tumor. Crit. Rev. Oncog. 2015;20:199–216. doi: 10.1615/CritRevOncog.2015013566. PubMed DOI PMC

Nesvick CL, Lafay-Cousin L, Raghunathan A, Bouffet E, Huang AA, Daniels DJ. Atypical teratoid rhabdoid tumor: Molecular insights and translation to novel therapeutics. J. Neurooncol. 2020;150:47–56. doi: 10.1007/s11060-020-03639-w. PubMed DOI PMC

Kim KH, Roberts CW. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Cancer Genet. 2014;207:365–372. doi: 10.1016/j.cancergen.2014.04.004. PubMed DOI PMC

Kuntz KW, et al. The importance of being me: Magic methyls, methyltransferase inhibitors, and the discovery of tazemetostat. J. Med. Chem. 2016;59:1556–1564. doi: 10.1021/acs.jmedchem.5b01501. PubMed DOI

Gounder M, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: An international, open-label, phase 2 basket study. Lancet Oncol. 2020;21:1423–1432. doi: 10.1016/S1470-2045(20)30451-4. PubMed DOI

Morschhauser F, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21:1433–1442. doi: 10.1016/S1470-2045(20)30441-1. PubMed DOI PMC

Reddy AT, et al. Efficacy of high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid/rhabdoid tumor: A report from the children's oncology group trial ACNS0333. J. Clin. Oncol. 2020;38:1175–1185. doi: 10.1200/JCO.19.01776. PubMed DOI PMC

Nemes K, et al. Infants and newborns with atypical teratoid rhabdoid tumors (ATRT) and extracranial malignant rhabdoid tumors (eMRT) in the EU-RHAB Registry: A unique and challenging population. Cancers. 2022;14:2185. doi: 10.3390/cancers14092185. PubMed DOI PMC

Slavc I, et al. Improved long-term survival of patients with recurrent medulloblastoma treated with a "MEMMAT-like" metronomic antiangiogenic approach. Cancers. 2022;14:5128. doi: 10.3390/cancers14205128. PubMed DOI PMC

Ferrari A, et al. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: The prospective NRSTS 2005 study by the European pediatric soft tissue sarcoma study group (EpSSG) Lancet Child Adolesc. Health. 2021;5:546–558. doi: 10.1016/S2352-4642(21)00159-0. PubMed DOI

Frühwald MC, et al. Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. Neuro. Oncol. 2020;22:1006–1017. doi: 10.1093/neuonc/noz244. PubMed DOI PMC

Steinbügl M, et al. Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors. Pediatr Blood Cancer. 2021;68:e29267. doi: 10.1002/pbc.29267. PubMed DOI

Witkowski L, et al. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. Gynecol. Oncol. 2016;141:454–460. doi: 10.1016/j.ygyno.2016.03.013. PubMed DOI PMC